- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
M Pharmaceutical's Trimeo Patent Allowed by Canadian Intellectual Property Office
M Pharmaceutical Inc. (CSE:MQ) announced the Canadian Intellectual Property Office has allowed M Pharmaceutical Inc.’s patent application 2,720,691, entitled “Bezoar-Forming Units for Weight Control,” to be issued.
M Pharmaceutical Inc. (CSE:MQ) announced the Canadian Intellectual Property Office has allowed M Pharmaceutical Inc.’s patent application 2,720,691, entitled “Bezoar-Forming Units for Weight Control,” to be issued. This patent was filed on April 28, 2009, and will remain in force for 20 years from that date.
The patent claims cover the design, composition, and methods to use bezoar-forming units that are temporary and dissolvable. This patent is fundamental to the design of M Pharma’s Trimeo capsules, currently under development for weight loss.
M Pharmaceutical CEO, Matthew Lehman, stated:
I am pleased to report that this patent will be issued in Canada. It is a key part of our intellectual property strategy to protect our investment in developing Trimeo for weight-loss applications in major global markets.
Connect with M Pharmaceutical Inc. (CSE:MQ) to receive an Investor Kit.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.